GleamWall
中文EN

PRLD Prelude Therapeutics Inc

Pharmaceutical Preparations · Nasdaq · SEC CIK 1678660 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY105.4%
TTM net income YoY52.3%
TTM EPS YoY59.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-283.9%
Net margin-247.1%
FCF margin-129.6%
EBITDA margin-277.0%

Returns

ROE-58.4%
ROA-39.5%
ROIC (approx.)-86.6%
Asset turnover0.16x

Leverage & solvency

Liabilities / assets29.3%
Debt / equity0.00x
Current ratio4.20x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.52x
Accruals ratio-18.8%
Payout ratio—
Capex / revenue0.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$5.65M$5.70M$4.58M$5.64M$6.50M$0$0$4.00M
R&D expense$14.83M$16.13M$13.60M$17.99M$21.71M$25.78M$28.82M$31.62M
SG&A expense$5.08M$5.03M$5.16M$5.00M$5.21M$6.41M$5.79M$6.21M
Operating income-$14.27M-$15.45M-$14.18M-$17.35M-$20.42M-$32.19M-$34.61M-$33.83M
Net income-$12.54M-$13.92M-$10.38M-$16.46M-$19.73M-$31.23M-$32.09M-$28.73M
EBITDA-$13.92M-$15.10M-$13.79M-$16.93M-$19.99M-$31.76M-$34.17M-$33.34M
EPS (basic)-0.12-0.14-0.13—-0.26-0.41-0.42—
EPS (diluted)-0.12-0.14-0.13—-0.26-0.41-0.42—
Weighted avg. shares (diluted)103.09M98.39M82.52M—76.13M75.99M75.99M—
Balance sheet
Cash & equivalents$23.41M$26.33M$21.76M$35.26M$47.53M$25.75M$40.27M$12.47M
Short-term investments$116.59M$125.43M$59.80M$67.96M$7.42M$47.46M$58.80M$121.14M
Current assets$142.43M$154.90M$84.59M$105.69M$58.33M$76.88M$102.40M$135.90M
PP&E, net$4.06M$4.40M$4.72M$5.11M$5.53M$5.96M$6.39M$6.77M
Total assets$175.49M$189.36M$119.64M$141.31M$94.75M$114.92M$141.26M$175.51M
Current liabilities$33.93M$38.04M$41.72M$52.99M$18.19M$20.91M$19.79M$25.64M
Total liabilities$51.35M$55.63M$59.46M$72.68M$36.22M$39.08M$38.08M$44.06M
Shareholders' equity$124.14M$133.73M$60.18M$68.64M$58.53M$75.84M$103.18M$131.46M
Cash flow statement
Operating cash flow-$13.78M-$15.57M-$21.68M$23.12M-$19.11M-$26.07M-$34.23M-$20.74M
Capital expenditure$35,000$0$0$0$0$20,000$47,000$53,000
Free cash flow-$13.81M-$15.57M-$21.68M$23.12M-$19.11M-$26.09M-$34.28M-$20.80M
Investing cash flow$9.02M-$65.50M$8.50M-$60.34M$40.09M$11.52M$62.19M$22.12M
Financing cash flow$1.17M$85.82M-$314,000$24.94M-$5,000$37,000-$160,000-$34,000
Depreciation & amortization$341,000$353,000$391,000$418,000$425,000$433,000$435,000$489,000
Stock-based compensation$2.03M$2.03M$2.00M$1.84M$2.42M$3.81M$3.83M$3.77M

Free plan shows the latest 8 periods; Pro shows all 31 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.